anti-PD-1 antibody

Phase 2Biologic

anti-PD-1 antibody is one of 219 biologic programs targeting Gastroesophageal Junction Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

218

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastroesophageal Junction AdenocarcinomaActive, not recruiting

LymphomaActive, not recruiting

Malignant MesotheliomaActive, not recruiting

Triple-Negative Breast CancerActive, not recruiting

Chronic Hepatitis B Virus InfectionActive, not recruiting

Pancreatic CancerActive, not recruiting

Solid TumorsSuspended

Gastroesophageal Junction AdenocarcinomaPhase 2

Active, not recruiting

LymphomaPhase 1

Active, not recruiting

Malignant MesotheliomaPhase 1/Phase 2

Active, not recruiting

Triple-Negative Breast CancerPhase 2

Active, not recruiting

Chronic Hepatitis B Virus InfectionPhase 2

Active, not recruiting

Pancreatic CancerPhase 2

Active, not recruiting

Solid TumorsPhase 1

Suspended

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

anti-PD-1 antibody

Boehringer Ingelheim

Phase 2

1 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Velban

EEastern Cooperative Oncology Group

Preclinical

15 4

Norvir

AbbVie

Preclinical

1 5

Nuvigil

NNuvo Research GmbH

Preclinical

1 6

PEG-Intron

Merck & Co.

Preclinical

1 7

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—8

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

3 9

Stem Cells

KKang Stem Biotech Co., Ltd.

Preclinical

2 10

Immune Checkpoint Inhibitor

IImmuneSensor Therapeutics Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Malignant Tumors

NCT05631886

Phase 1Active, not recruiting

Advanced/metastatic Solid Tumors

NCT05631899

Phase 2Recruiting

Chronic Hepatitis B Virus Infection

NCT05769816

Phase 2Recruiting

Chronic Hepatitis B Virus Infection

NCT05771402

Q3 2027

Phase 1/2Recruiting

Patients With Advanced Solid Tumors

NCT05204862

Clinical

Trials by Indication[1]

Pancreatic Cancer3 trials

Combination of Radiation Therapy and Anti-PD-1 Antibody in Treating Patients With Pancreatic Cancer

Unknown status·SShixiu Wu·Phase 2·NCT03374293·21 enrolled

An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer

Unknown status·—·Phase 1/2·NCT03989310·50 enrolled

SBRT and Anti-programmed Cell Death Protein 1(Anti-PD-1) in Late Stage or Recurrent Pancreatic Cancer Patients

Terminated·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT03716596·8 enrolled

Immunotherapy2 trials

A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC

Unknown status·—·Phase 1/2·NCT04004234·20 enrolled

Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases

Completed·—·Phase 1/2·NCT03757858·40 enrolled

Chronic Hepatitis B Virus Infection2 trials

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (A)

Recruiting·TThe Second Affiliated Hospital of Chongqing Medical University·Phase 2·NCT05769816·120 enrolled

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B)

Recruiting·TThe Second Affiliated Hospital of Chongqing Medical University·Phase 2·NCT05771402·120 enrolled

Phase 11 trial

A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6

Completed·IIntensity Therapeutics, Inc.·Phase 1/2·NCT03058289·111 enrolled

Patients With Advanced Solid Tumors1 trial

Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors

Recruiting·TTiumBio Co., Ltd.·Phase 1/2·NCT05204862·240 enrolled

9 more indications

Triple-Negative Breast Cancer1 trial

Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer

Unknown status·—·Phase 2·NCT05402722·30 enrolled

Advanced Malignant Tumors1 trial

Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors

Completed·NNanjing Leads Biolabs Co.,Ltd·Phase 1/2·NCT05223231·26 enrolled

Malignant Tumors1 trial

Combination of CAR-DC Vaccine and ICIs in Malignant Tumors

Recruiting·—·Phase 1·NCT05631886·10 enrolled

Malignant Mesothelioma1 trial

Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma

Terminated·—·Phase 1/2·NCT03393858·10 enrolled

Advanced/Metastatic Solid Tumors1 trial

CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors

Active, not recruiting·—·Phase 1·NCT05631899·9 enrolled

Relapsed or Refractory1 trial

Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies

Recruiting·HHan weidong·Phase 1/2·NCT02961101·250 enrolled

Lymphoma1 trial

A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas

Unknown status·—·Phase 1·NCT03991559·20 enrolled

Gastroesophageal Junction Adenocarcinoma1 trial

PD-1 Antibody + XELOX in 1st Line Serum A-fetoprotein (AFP)-Elevated Gastric or Gastroesophageal Junction Adenocarcinoma

Unknown status·—·Phase 2·NCT04098796·30 enrolled

Solid Tumors1 trial

Phase I Open-label, Dose Escalation Trial of BI 1831169 Monotherapy and in Combination With an Anti-PD-1 mAb in Patients With Advanced or Metastatic Solid Tumors

Suspended· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT05155332·190 enrolled

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for anti-PD-1 antibody. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — anti-PD-1 antibody compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for anti-PD-1 antibody. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: Boehringer Ingelheim

anti-PD-1 antibody

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Trials by Indication[1]

Pancreatic Cancer3 trials

Immunotherapy2 trials

Chronic Hepatitis B Virus Infection2 trials

Phase 11 trial

Patients With Advanced Solid Tumors1 trial

Triple-Negative Breast Cancer1 trial

Advanced Malignant Tumors1 trial

Malignant Tumors1 trial

Malignant Mesothelioma1 trial

Advanced/Metastatic Solid Tumors1 trial

Relapsed or Refractory1 trial

Lymphoma1 trial

Gastroesophageal Junction Adenocarcinoma1 trial

Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News